Alivus Life Sciences Limited

Valuation premium: PE 28.22 leaves limited buffer if growth slows—verify how this compares to peers and ALIVUS's historical range.

Margin volatility: OPM swings between 26.51% (Sep 2024) and 34.37% (Dec 2025). Clarify whether swings reflect seasonal patterns, product mix, input costs, or pricing pressure.

Revenue base modest with quarter-to-quarter volatility (₹506–₹689 Crore); identify whether volatility is normal cyclicality or signals demand instability.

Promoter concentration at 74.87% with public float just 12.41% limits institutional investor access and governance oversight—verify any pledges or lock-in structures.

EPS grew 68% (₹7.78 to ₹13.04, Sep 2024–Jun 2026) while revenue grew 26%, driven by operating margin expansion from 28.63% (Jun 2025) to 33.06% (Jun 2026)—verify if sustainable.

Net profit growth of 67% over two years (₹95 Cr to ₹160 Cr) outpaced revenue growth, signaling either improved product mix, pricing power, or cost control—clarify which.

ROE 18.36% with zero debt indicates efficient capital deployment; balance sheet capacity exists for organic investment or M&A—track capex and R&D spending to assess growth priorities.

Recent dividend activity (Sep 2025) signals cash confidence; monitor payout ratio to assess how much earnings are retained for reinvestment versus distribution.